Cns Pharmaceuticals Inc CNSP

NAS: CNSP | ISIN: US18978H1023   14/11/2024
0,119 USD (-4,80%)
(-4,80%)   14/11/2024

29 maart 2023 · CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event · Persbericht

13 maart 2023 · CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues · Persbericht

9 maart 2023 · CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland · Persbericht

7 februari 2023 · CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM · Persbericht

12 januari 2023 · CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland · Persbericht

5 januari 2023 · CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event · Persbericht

3 januari 2023 · CNS Pharmaceuticals Appoints Faith L. Charles, JD as Chair of the Board of Directors · Persbericht

8 december 2022 · CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM) · Persbericht

5 december 2022 · CNS Pharmaceuticals to Participate at the Virtual Investor "Ask the CEO" Event · Persbericht

1 december 2022 · CNS Pharmaceuticals Announces Pricing of $6.0 Million Public Offering At a Premium to the Market Closing Price · Persbericht

28 november 2022 · CNS Pharmaceuticals Announces Reverse Stock Split · Persbericht

14 november 2022 · CNS Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

2 november 2022 · CNS Pharmaceuticals Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM · Persbericht

10 oktober 2022 · CNS Pharmaceuticals to Participate in The American Brain Tumor Association's Breakthrough (ABTA) for Brain Tumors® 5K (BT5K) Run · Persbericht

28 september 2022 · CNS Pharmaceuticals Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM · Persbericht

23 september 2022 · CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM) · Persbericht

7 september 2022 · CNS Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference · Persbericht

15 augustus 2022 · CNS Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update · Persbericht

25 juli 2022 · CNS Pharmaceuticals Urges Shareholders to Vote in Favor of Proxy Proposals for the Upcoming Annual Meeting of Shareholders on July 27, 2022 · Persbericht

23 juni 2022 · CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM · Persbericht

Mijn selecties